Alzheimer disease (AD) is the most common type of dementia which is becoming a primary problem in the present society, but it lacks effective treatment methods and means of AD. Tanshinone IIA (Tan IIA) has been reported to have neuroprotective effects to restrain the Aβ25-35-mediated apoptosis. However, few studies try to understand how Aβ1-42 affects hyperphosphorylation of tau and how Tan IIA regulates this process at the molecular level.
Methods:
Fifty male Sprague-Dawley rats were randomly divided into 5 groups and infused through the lateral ventricle with Aβ1-42 except the control group. Then the rats were treated with Tan IIA through intragastric administration for 4 weeks. After the ability of learning and memory being measured, histomorphological examination and Western blot were used to detect the possible mechanism in the AD-associated model rats.
Results:
We observed that Aβ1-42 infusion could induce spatial learning and memory deficits in rats. Simultaneously, Aβ1-42 also could reduce the neuron in cornu ammonis 1 and dentate gyrus of hippocampus, as well as increase the levels of cleaved caspase 3, hyperphosphorylated tau at the sites Ser396, Ser404, and Thr205 with enhancing staining of black granules in brain. We also found that Aβ1-42 could increase the activity of extracellular signal-regulated protein kinase (ERK) and glycogen synthase kinase-3β (GSK-3β). Meanwhile, these phenomena could be ameliorated when Tan IIA was used.
Conclusion:
We concluded that Tan IIA might have neuroprotective effect and improving learning and memory ability to be a viable candidate in AD therapy with mechanisms involving the ERK and GSK-3β signal pathway.
HuangHCJiangZF. Accumulated amyloid-beta peptide and hyperphosphorylated tau protein: relationship and links in Alzheimer’s disease. J Alzheimers Dis. 2009;16(1):15–27.
2.
Grundke-IqbalIIqbalKQuinlanMTungYCZaidiMSWisniewskiHM. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem. 1986;261(13):6084–6089.
3.
BernardoAMcCordMTroenAMAllisonJDMcDonaldMP. Impaired spatial memory in APP overexpressing mice on a homocysteinemia-inducing diet. Neurobiol Aging. 2007;28(8):1195–1205.
4.
LongZZengQWangKSharmaAHeG. Gender difference in valproic acid-induced neuroprotective effects on APP/PS1 double transgenic mice modeling Alzheimer’s disease. Acta Biochim Biophys Sin (Shanghai). 2016;48(10):930–938.
5.
GrimaldiABrighiCPeruzziG. Inflammation, neurodegeneration and protein aggregation in the retina as ocular biomarkers for Alzheimer’s disease in the 3xTg-AD mouse model. Cell Death Dis. 2018;9(6):685.
6.
OngWYWuYJFarooquiTFarooquiAA. Qi fu yin-a ming dynasty prescription for the treatment of dementia. Mol Neurobiol. 2018;55(9):7389–7400.
7.
HugelHMJacksonN. Danshen diversity defeating dementia. Bioorg Med Chem Lett. 2014;24(3):708–716.
8.
FanGWGaoXMWangH. The anti-inflammatory activities of Tanshinone IIA, an active component of TCM, are mediated by estrogen receptor activation and inhibition of iNOS. J Steroid Biochem Mol Biol. 2009;113(3-5):275–280.
9.
FuJHuangHLiuJPiRChenJLiuP. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. Eur J Pharmacol. 2007;568(1-3):213–221.
10.
LiuTJinHSunQRXuJHHuHT. The neuroprotective effects of tanshinone IIA on beta-amyloidinduced toxicity in rat cortical neurons. Neuropharmacology. 2010;59(7-8):595–604.
11.
HuHZhaiCQianG. Protective effects of tanshinone IIA on myocardial ischemia reperfusion injury by reducing oxidative stress, HMGB1 expression, and inflammatory reaction. Pharm Biol. 2015;53(12):1752–1758.
12.
XuQQXuYJYangC. Sodium tanshinone IIA sulfonate attenuates scopolamine-induced cognitive dysfunctions via improving cholinergic system. Biomed Res Int. 2016;2016:9852536.
13.
ZhouYLiWXuLChenL. In Salvia miltiorrhiza, phenolic acids possess protective properties against amyloid beta-induced cytotoxicity, and tanshinones act as acetylcholinesterase inhibitors. Environ Toxicol Pharmacol. 2011;31(3):443–452.
14.
MedinaMAvilaJ. New insights into the role of glycogen synthase kinase-3 in Alzheimer’s disease. Expert Opin Ther Targets. 2014;18(1):69–77.
15.
Llorens-MartinMJuradoJHernandezFAvilaJ. GSK-3beta, a pivotal kinase in Alzheimer disease. Front Mol Neurosci. 2014;7:46.
16.
LiangSHChenJMNormandinMD. Discovery of a highly selective glycogen synthase kinase-3 inhibitor (PF-04802367) that modulates tau phosphorylation in the brain: translation for PET neuroimaging. Angew Chem Int Ed Engl. 2016;55(33):9601–9605.
17.
WangJZXiaYYGrundke-IqbalIIqbalK. Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. J Alzheimers Dis. 2013;33(suppl 1):S123–S139.
18.
PlattnerFAngeloMGieseKP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem. 2006;281(35):25457–25465.
19.
ScalaFFuscoSRipoliC. Intraneuronal Abeta accumulation induces hippocampal neuron hyperexcitability through A-type K(+) current inhibition mediated by activation of caspases and GSK-3. Neurobiol Aging. 2015;36(2):886–900.
20.
BaxBCarterPSLewisC. The structure of phosphorylated GSK-3beta complexed with a peptide, FRATtide, that inhibits beta-catenin phosphorylation. Structure. 2001;9(12):1143–1152.
21.
DozzaBSmithMAPerryGTabatonMStrocchiP. Regulation of glycogen synthase kinase-3beta by products of lipid peroxidation in human neuroblastoma cells. J Neurochem. 2004;89(5):1224–1232.
SawamuraNGongJSGarverWS. Site-specific phosphorylation of tau accompanied by activation of mitogen-activated protein kinase (MAPK) in brains of Niemann-Pick type C mice. J Biol Chem. 2001;276(13):10314–10319.
24.
ZhuLQWangSHLingZQWangQHuMQWangJZ. Inhibition of melatonin biosynthesis activates protein kinase a and induces Alzheimer-like tau hyperphosphorylation in rats. Chin Med Sci J. 2005;20(2):83–87.
25.
YinYYLiuHCongXB. Acetyl-L-carnitine attenuates okadaic acid induced tau hyperphosphorylation and spatial memory impairment in rats. J Alzheimers Dis. 2010;19(2):735–746.
26.
LiuSJZhangAHLiHL. Overactivation of glycogen synthase kinase-3 by inhibition of phosphoinositol-3 kinase and protein kinase C leads to hyperphosphorylation of tau and impairment of spatial memory. J Neurochem. 2003;87(6):1333–1344.
27.
YamamotoTHiranoA. A comparative study of modified Bielschowsky, Bodian and thioflavin S stains on Alzheimer’s neurofibrillary tangles. Neuropathol Appl Neurobiol. 1986;12(1):3–9.
28.
ZouKKimDKakioA. Amyloid beta-protein (Abeta)1-40 protects neurons from damage induced by Abeta1-42 in culture and in rat brain. J Neurochem. 2003;87(3):609–619.
29.
SisodiaSS. Alzheimer’s disease: perspectives for the new millennium. J Clin Invest. 1999;104(9):1169–1170.
30.
TeixeiraJSilvaTAndradePBBorgesF. Alzheimer’s disease and antioxidant therapy: how long how far?Curr Med Chem. 2013;20(24):2939–2952.
31.
RussoPFrustaciADelBAFiniMCesarioA. From traditional European medicine to discovery of new drug candidates for the treatment of dementia and Alzheimer’s disease: acetylcholinesterase inhibitors. Curr Med Chem. 2013;20(8):976–983.
32.
LaiCYWuMYChiangJH. Utilization of Western medicine and traditional Chinese medicine among patients with Alzheimer’s disease in Taiwan: a nationwide population-based study. Eur J Neurol. 2017;24(9):1166–1172.
33.
HsuCHWangSELinCLHsiaoCJSheuSJWuCH. Neuroprotective effects of the herbal formula B401 in both cell and mouse models of Alzheimer’s disease. Evid Based Complement Alternat Med. 2016;2016:1939052.
34.
WangTWuZSunLLiWLiuGTangY. A computational systems pharmacology approach to investigate molecular mechanisms of herbal formula tian-ma-gou-teng-yin for treatment of Alzheimer’s disease. Front Pharmacol. 2018;9:668.
35.
ParkEJZhaoYZKimYCSohnDH. PF2401-SF, standardized fraction of Salvia miltiorrhiza and its constituents, tanshinone I, tanshinone IIA, and cryptotanshinone, protect primary cultured rat hepatocytes from bile acid-induced apoptosis by inhibiting JNK phosphorylation. Food Chem Toxicol. 2007;45(10):1891–1898.
36.
ShiLLYangWNChenXL. The protective effects of tanshinone IIA on neurotoxicity induced by beta-amyloid protein through calpain and the p35/Cdk5 pathway in primary cortical neurons. Neurochem Int. 2012;61(2):227–235.
37.
ShanHLiXPanZ. Tanshinone IIA protects against sudden cardiac death induced by lethal arrhythmias via repression of microRNA-1. Br J Pharmacol. 2009;158(5):1227–1235.
38.
DongHMaoSWeiJ. Tanshinone IIA protects PC12 cells from beta-amyloid(25-35)-induced apoptosis via PI3K/Akt signaling pathway. Mol Biol Rep. 2012;39(6):6495–6503.
39.
MengXFZouXJPengBShiJGuanXMZhangC. Inhibition of ethanol-induced toxicity by tanshinone IIA in PC12 cells. Acta Pharmacol Sin. 2006;27(6):659–664.
40.
AlonsoADGrundke-IqbalIBarraHSIqbalK. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc Natl Acad Sci U S A. 1997;94(1):298–303.
41.
TakashimaA. Hyperphosphorylated tau is a cause of neuronal dysfunction in tauopathy. J Alzheimers Dis. 2008;14(4):371–375.
42.
Mondragon-RodriguezSPerryGLuna-MunozJAcevedo-AquinoMCWilliamsS. Phosphorylation of tau protein at sites Ser(396-404) is one of the earliest events in Alzheimer’s disease and Down syndrome. Neuropathol Appl Neurobiol. 2014;40(2):121–135.
43.
CowanCMBossingTPageAShepherdDMudherA. Soluble hyper-phosphorylated tau causes microtubule breakdown and functionally compromises normal tau in vivo. Acta Neuropathol. 2010;120(5):593–604.
44.
NobleWHangerDPMillerCCLovestoneS. The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol. 2013;4:83.
45.
RobersonEDScearce-LevieKPalopJJ. Reducing endogenous tau ameliorates amyloid beta induced deficits in an Alzheimer’s disease mouse model. Science. 2007;316(5825):750–754.
46.
SelenicaMLJensenHSLarsenAK. Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol. 2007;152(6):959–979.
47.
LiTPaudelHK. Glycogen synthase kinase 3beta phosphorylates Alzheimer’s disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. Biochemistry-Us. 2006;45(10):3125–3133.
48.
TakashimaA. GSK-3beta and memory formation. Front Mol Neurosci. 2012;5:47.
49.
LiXHLvBLXieJZLiuJZhouXWWangJZ. AGEs induce Alzheimer-like tau pathology and memory deficit via RAGE-mediated GSK-3 activation. Neurobiol Aging. 2012;33(7):1400–1410.
50.
IllenbergerSZheng-FischhoferQPreussU. The endogenous and cell cycle-dependent phosphorylation of tau protein in living cells: implications for Alzheimer’s disease. Mol Biol Cell. 1998;9(6):1495–1512.
51.
CaiTCheHYaoT. Manganese induces tau hyperphosphorylation through the activation of ERK MAPK pathway in PC12 cells. Toxicol Sci. 2011;119(1):169–177.
52.
KlafkiHWLewczukPKamrowski-KruckH. Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form. J Alzheimers Dis. 2009;18(3):613–622.
GhasemiRZarifkarARastegarKMaghsoudiNMoosaviM. Insulin protects against Abeta-induced spatial memory impairment, hippocampal apoptosis and MAPK signaling disruption. Neuropharmacology. 2014;85:113–120.
55.
TownsendMMehtaTSelkoeDJ. Soluble Abeta inhibits specific signal transduction cascades common to the insulin receptor pathway. J Biol Chem. 2007;282(46):33305–33312.
56.
LiuMYWangSYaoWF. Memantine improves spatial learning and memory impairments by regulating NGF signaling in APP/PS1 transgenic mice. Neuroscience. 2014;273:141–151.
57.
SavageMJLinYGCiallellaJRFloodDGScottRW. Activation of c-Jun N-terminal kinase and p38 in an Alzheimer’s disease model is associated with amyloid deposition. J Neurosci. 2002;22(9):3376–3385.
58.
KirouacLRajicAJCribbsDHPadmanabhanJ. Activation of Ras-ERK signaling and GSK-3 by amyloid precursor protein and amyloid beta facilitates neurodegeneration in Alzheimer’s disease. eNeuro. 2017;4(2):1–21.
59.
TakashimaAMurayamaMMurayamaO. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci U S A. 1998;95(16):9637–9641.
